Journal: Annals of Translational Medicine

Article Title: Hyperion imaging system reveals heterogeneous tumor microenvironment of oral squamous cell carcinoma patients at T1N0M0 stage

doi: 10.21037/atm-20-7194

Figure Lengend Snippet: Antibodies targeting the tumor environment of oral squamous cell carcinoma (OSCC)

Article Snippet: CD274/PD-L1 , Nd150 , E1L3N , Fluidigm , 3150031D.

Techniques:

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Programmed death-ligand 1 (PD-L1) topology and the immunogen of both antibody clone E1L3N and 22C3.

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques:

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Representative PD-L1 TPS for two clones at three cutoffs (immunohistochemistry, ×10). For 22C3, (A) PD-L1 with no staining (score: 0%); (B) PD-L1 score in the range of 1–49%; (C) PD-L1 score ≥ 50%. For E1L3N, (D) PD-L1 negative (score: 0%); (E) PD-L1 score in the range from 1–49%; (F) PD-L1 score ≥ 50%.

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques: Clone Assay, Immunohistochemistry, Staining

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Immunofluorescence staining of PD-L1 antibodies on biopsy samples (40×). (A) Red signal for clone 22C3; (B) green signal for clone E1L3N.

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques: Immunofluorescence, Staining

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Programmed death-ligand 1 (PD-L1) scoring distribution and comparison of the two clones expression. (A) PD-L1 TPS distribution (22C3 vs. E1L3N) by scatter plot; (B) the difference value (22C3 vs. E1L3N) by Bland-Altman plot; (C) Nonliar fit curve for two clones (22C3 vs. E1L3N).

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques: Comparison, Clone Assay, Expressing

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Programmed death-ligand 1 (PD-L1) scoring and the concordance between the two pathologists. (A) Scatter plot (Pathologist A vs. Pathologist B) for 22C3; (B) Bland-Altman plot (Pathologist A vs. Pathologist B) for 22C3; (C) Nonliar fit curve of the two pathologists (Pathologist A vs. Pathologist B) for 22C3; (D) Scatter plot of the two pathologists (Pathologist A vs. Pathologist B) for E1L3N; (E) Bland-Altman plot of the two pathologists (Pathologist A vs. Pathologist B) for E1L3N; (F) Nonliar fit curve of the two pathologists (Pathologist A vs. Pathologist B) for E1L3N.

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques:

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: Positive percentage of PD-L1 for two clones based on two cutoffs value

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques: Clone Assay

Journal: Translational Cancer Research

Article Title: High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

doi: 10.21037/tcr-20-101

Figure Lengend Snippet: The concordance of evaluating the two PD-L1 antibody clones between pathologists

Article Snippet: Also, the intra-cellular domain of the E1L3N immunogen was different from 22C3, whose immunogen was located in the extra-cellular domain containing four glycosylated sites, which might affect the affinity between the PD-L1 epitope and its antibody.

Techniques: Clone Assay

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

doi: 10.1097/pai.0000000000000531

Figure Lengend Snippet: FIGURE 2. Western blot and microphotographs of representative examples from PD-L1 clones validation (A and B). PD-L1 MW area from human tonsil cell line, human lung cancer cell lines (H23, H157, H461, H4006, H1171, H193), HEK293, and HEK293- PD-L1 transfected are showing using PD-L1 E1L3N (A), E1J2J (B), SP142 (C), 28-8 (D), 22C3 (E), SP362 (F) 5H1(G) clones, and b- actin (H) by Western blot and immunohistochemistry. Positive membrane staining (brown) and negative PD-L1 staining are shown in reactive tonsil tissue, human placenta, cell pellet from HEK293-PD-L1 nontransfected and transfected cell line. HEK293 indicates human embryonic kidney 293 cell line; MW, molecular weight; PD-L1, programmed cell death ligand 1; transf., transfected.

Article Snippet: Published by Wolters Kluwer Health, Inc. tumor compartment was 28.34% with E1L3N, 81.90% with E1J2J, 55.98% with SP142, 57.65% with 28-8, 26.36% with 22C3, and 62.37% with SP263 clone (Table 3).

Techniques: Western Blot, Clone Assay, Biomarker Discovery, Transfection, Immunohistochemistry, Membrane, Staining, Molecular Weight

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

doi: 10.1097/pai.0000000000000531

Figure Lengend Snippet: FIGURE 3. Microphotographs of representative examples of IHC PD-L1 heterogeneity expression in MCs from lung cancer specimens. Positive membrane staining (brown) and negative PD-L1 staining are shown with PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP362 clone.4 magnification and detail at200 magnification. IHC indicates immunohistochemistry; MCs, ma- lignant cells; PD-L1, programmed cell death ligand 1.

Article Snippet: Published by Wolters Kluwer Health, Inc. tumor compartment was 28.34% with E1L3N, 81.90% with E1J2J, 55.98% with SP142, 57.65% with 28-8, 26.36% with 22C3, and 62.37% with SP263 clone (Table 3).

Techniques: Expressing, Membrane, Staining, Immunohistochemistry

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

doi: 10.1097/pai.0000000000000531

Figure Lengend Snippet: FIGURE 5. Microphotographs of representative examples of IHC PD-L1 heterogeneity expression in TAICs in TMA lung cancer specimens. Positive membrane staining (brown) in macrophages (A) and lymphocytes (B) are shown with PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 clone. 4 magnification and detail at 200 magnification. IHC indicates immunohistochemistry; PD-L1, programmed cell death ligand 1; TAICs, tumor-associated inflammatory cells; TMA, tissue microarrays.

Article Snippet: Published by Wolters Kluwer Health, Inc. tumor compartment was 28.34% with E1L3N, 81.90% with E1J2J, 55.98% with SP142, 57.65% with 28-8, 26.36% with 22C3, and 62.37% with SP263 clone (Table 3).

Techniques: Expressing, Membrane, Staining, Immunohistochemistry